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Summary
EGFRvIII is a constitutively activated truncated variant of the epidermal growth factor receptor (EGFR)
which has been shown to increase tumorgenicity. There are conflicting reports on the extent of EGFRvIII
expression in tissues which may in part stem from the use of different assay methodologies. We investigated
the expression of both EGFRvIII and wild-type EGFR (EGFRwt) in cell lines and primary breast cancers.
First, we used a RT-PCR assay that can simultaneously measure EGFRwt and EGFRvIII mRNA to
screen 55 tumor cell lines. We show that except for EGFRvIII transfected cells, only EGFRwt was de-
tected. We then validated a real-time PCR assay and used this to screen 170 formalin fixed paraffin-
embedded primary breast cancers for evidence of EGFRwt and EGFRvIII expression. No samples were
positive for EGFRvIII expression except for control transfectants and glioblastomas. In contrast, EGFRwt
was expressed at varying levels in the majority of samples tested. We conclude that the expression of
EGFRvIII is extremely rare in breast cancer and therefore it does not contribute to the malignant phe-
notype.
Abbreviations: CYP: cyclophilin; EGFR: epidermal growth factor receptor; EGFRvIII: epidermal growth
factor receptor variant III; FPET: formalin fixed paraffin-embedded tissue; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase
Introduction
The epidermal growth factor receptor (EGFR) is a
170 kd transmembrane protein which exhibits
intrinsic tyrosine kinase activity following the
binding of one of its cognate ligands. Activation of
EGFR leads to many cellular responses including
mitogenesis and cellular proliferation [1]. Overex-
pression and/or amplification of EGFR has been
found in many human tumors including, gastric,
esophageal, breast, prostate, glioblastoma and
lung, and has been associated with poor prognosis
[2]. These factors make EGFR an attractive target
for tumor specific therapies and several com-
pounds aimed at inhibiting EGFR signaling are
now in clinical trials [3]. However, this receptor is
also expressed in many normal tissues including
the liver and skin and therefore drugs designed to
disrupt EGFR activity could have severe side af-
fects. Therefore, targeting growth factor receptors
with more restrictive expression in tumors but not
normal tissues would, in theory, be less likely to
cause side effects. A potential tumor specific
growth receptor may be EGFRvIII. This receptor
is a mutant or variant form of the EGFR which
contains an 801-bp in-frame deletion that lacks
exons 2–7 resulting in the production of a consti-
tutively active truncated receptor without the
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traditional ligand binding domain [4–6]. This form
of the receptor was originally discovered in a
glioblastoma and subsequent studies suggested
that it is also expressed in breast and non-small cell
lung carcinomas but not in normal tissues [7–9]. In
contrast, a recent publication using antibodies
tested for specificity towards wild-type EGFR
(EGFRwt) and EGFRvIII was unable to detect
the variant in any tumors outside the brain [10].
Most of these studies relied on immunohisto-
chemical techniques to examine EGFRvIII
expression. Unfortunately, the antibodies used
may cross-react with other proteins including
EGFRwt and may produce equivocal results.
Although detection of EGFRvIII mRNA is not
conclusive proof of protein expression, the ab-
sence of the message would rule out expression.
Two published reports where RT-PCR was used
to measure EGFRvIII and wild-type EGFR
message in a small number of primary breast
cancers specimens have produced conflicting re-
sults. The results by Ge et al. [9] suggest that
EGFRvIII is expressed in the majority of pri-
mary breast cancers (19/28) while Tidow et al.
[11] were unable to detect this variant form of
EGFR in any of the 23 primary breast cancers
analyzed. We set out to definitively answer this
question by examining EGFRvIII expression at
the RNA level in a comprehensive panel of
breast cancer cell lines and 153 cases of invasive
ductal carcinoma and 17 cases of invasive lobular
carcinoma, using RT-PCR and a validated specific
and sensitive real-time PCR assay. We chose to
look at breast cancer in order to determine the
potential of EGFRvIII as a therapeutic target and
to attempt to clarify the inconsistency in the lit-
erature.
Materials and methods
Cell lines and culture conditions
Tumor cell lines were originally obtained from the
Lombardi Cancer Center Tissue Culture Shared
Resource at Georgetown University (Washington,
DC) and maintained at 37 C in a 5% CO2
atmosphere in improved minimal essential med-
ium (Biosource International, CA) supplemented
with 10% fetal bovine serum (Valley Biomedical
Products, VA).
Paraffin-embedding cell lines
In order to validate our real-time PCR assays we
formalin fixed, paraffin embedded tumor cells with
varying expression levels of EGFRwt and EG-
FRvIII. The controls for EGFRwt mRNA
expression included MDA MB 468 (high expres-
sion), MCF-7 (low expression), MDA MB 435
(undetectable) cells, none of which express EG-
FRvIII. The positive controls for EGFRvIII in-
cluded MCF-7 breast cancer cells transfected with
an EGFRvIII expression construct (MCF-7/EG-
FRvIII) as described previously [12]. For addi-
tional controls, we purchased formalin fixed,
paraffin-embedded glioblastoma samples from
Clinomics Biosciences Inc. (Pittsfield, MA). Cell
lines were trypsinized, centrifuged, washed with
1 · PBS and 106 cells were added to 15 ml tubes.
Next the cells were suspended in 500 ll of freshly
prepared bovine plasma (Sigma # P-4639) and clot
formation initiated by adding 100 ll of 1000 U/ml
Thrombin (Sigma # T-4648). After 10 min incu-
bation at room temperature, cell pellets were for-
malin fixed in 10% buffered formalin for several
hours and then paraffin-embedded.
Primary breast cancer specimens
A total 170 primary breast cancers were examined
which included 153 invasive ductal carcinomas
and 17 invasive lobular carcinomas. The specimens
were obtained in a research protocol approved by
the Providence Saint Joseph Medical Center,
Burbank, CA. Surgery was performed between
1990 and 1997. One 5-lm section from the most
representative block was stained by H&E and
confirmed by histopathology to contain invasive
breast carcinoma. The RNA was extracted from
three 10-lm sections of the most representative
block, without dissection.
RNA isolation
Total RNA from cell lines was isolated from tu-
mor cells using Trizol Reagent (Invitrogen, CA).
Yield and quality were determined by spectro-
photometry (Beckman DU 640, Beckman Coul-
ter, Inc., Fullerton, CA) and using a Bioanalyzer
RNA 6000 Nano chip (Agilent Technologies, Palo
Alto, CA). All samples were stored at )80 C.
Total RNA was extracted from formalin fixed
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paraffin embedded cell lines (104–105 cells) and
tissue samples (3–6, 10 lm sections) using the
MasterPure RNA Purification Kit (Epicentre
Madison, WI) according to the manufacturer’s
instructions. The recovered RNA pellet was wa-
shed twice with 1 ml 75% ethanol and resuspended
in 30 ll nuclease-free water. All samples were
DNase treated and assayed for residual genomic
DNA using the real-time PCR assay for b-actin as
described below. The yield of total RNA for FPET
primary breast cancer specimens was 3.9 ± 3.0 lg
(mean ± SD, n ¼ 170).
RT-PCR
Random primers were used to reverse transcribe
1 lg total RNA from cell lines using the Reverse
Transcription System (Promega, Madison, WI)
and resulting cDNA diluted to a total of 100 ll in
TE buffer pH 8.0. PCR was performed using an
iCycler Thermal Cycler (Bio-Rad, Hercules, CA).
A 50 ll reaction containing 5 ll cDNA, 45 ll
Platinum PCR Supermix (Invitrogen, CA) and
250 nM of each primer was run using the follow-
ing cycle conditions: 3 min denaturing at 94 C
followed by 35 cycles of 94 C for 45 s, 60 C for
45 s, and 72 C for 2 min followed by a final 72 C
incubation for 7 min. We used the same primer
sequenced described by Luo et al. [13] and Ge et al.
[9] and purchased the oligonucleotides from Inte-
grated DNA Technologies, Inc. (Coralville, IA)
with forward primer sequence 5¢-ATG CGA CCC
TCC GGG ACG-3¢ and reverse sequence 5¢-GAG
TAT GTG TGA AGG AGT-3¢. As a control for
RNA loading, we amplified human GAPDH using
the forward primer 5¢-GAA GGT GAA GGT
CGG AGT C-3¢ and reverse 5¢-GAA GAT GGT
GAT GGG ATT TC-3¢. The cycle conditions
were: denaturing at 94 C for 2 min followed by 35
cycles of 94 C for 30 s, 55 C for 30 s, and 72 C
for 30 s followed by a final 72 C incubation for
5 min. The RT-PCR products were resolved on a
2% agarose gel (Invitrogen, CA), stained with
SYBR Green 1 (Molecular probes, OR) and
visualized using an EDAS 290 Camera (Eastman
Kodak Company, NY).
Genomic DNA detection
Prior to real-time PCR analysis, RNA extracts
from formalin fixed paraffin embedded samples
were tested for the presence of residual genomic
DNA (gDNA). Primers and a dual labeled fluor-
ogenic probe were used to detect b-actin. The
primers were forward 5¢-CAG CAG ATG TGG
ATC AGC AAG-3¢, reverse 5¢-GCA TTT GCG
GTG GAC GAT-3¢ and internal probe 5¢-FAM-
AGG AGT ATG ACG AGT CCG GCC CC-
BHQ1-3¢C. PCR was carried out with the Taq-
man Universal PCR Master Mix, without Am-
pErase UNG (ABI, Foster City, CA). The cycle
conditions were: denaturing at 94 C for 10 min.
followed by 40 cycles of 95 C for 20 s, 60 C for
45 s. Reactions were performed in a 5 ll reaction
on an ABI PRISM 7900HT Detection System.
Since there was no reverse transcription step, any
signal generated must be from residual gDNA. If
any samples generated a threshold PCR amplifi-
cation cycle time (CT value) of 36 (with threshold
set at 0.2) or lower in this assay, it was re-DNase
treated until the signal from this assay was above a
CT value of 36 (with threshold set at 0.2).
Real-time RT-PCR
Expression of EGFRwt, EGFRvIII as well as two
reference normalization genes, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and cyclo-
philin (CYP), were measured in paraffin-embedded
samples by a two-step real-time RT-PCR method
using the TaqMan Universal PCR Master Mix,
without AmpErase UNG (ABI, Foster City, CA).
Copy DNA (cDNA) was generated using the
SuperScript First Strand Synthesis System for RT-
PCR (Invitrogen, CA). Briefly, 100–500 ng total
RNA was reverse-transcribed using 50 lm ran-
dom hexamers, 1 lM of each gene specific primer
(see below), 25 mM MgCl2, 10 mM dNTPs, 0.1 M
DTT and 50 units Superscript II. The RT-PCR
reaction was incubated in a MJ Thermocycler (MJ
Research Inc., MA) under the following condi-
tions: 42 C for 2 min, 25 C for 10 min, 42 C for
50 min and 70 C for 15 min. The first strand
cDNA was then used as a template for the Taq-
Man assay (1 ng RNA equivalent per well per
plate). Sequences for the primers and probes
were generated using either Primer Express (ABI,
Foster City, CA) or Primer 3 software (http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_
www.cgi). The specificity of the primer and probe
sequences were confirmed by the UCSC Genome
Bioinformatics BLAT program (http://genome.
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ucsc.edu/cgi-bin/hgBlat?command=start & org=
human). The primers used were as follows: EG-
FRvIII forward 5¢-GAG TCG GGC TCT GGA
GGA AAA G-3¢, reverse 5¢-CCA CAG GCT
CGG ACG CAC-3¢ and internal probe 5¢-FAM-
AGC CGT GAT CTG TCA CCA CAT AAT
TAC C-BHQ1-3¢; EGFRwt forward 5¢-TGT CGA
TGG ACT TCC AGA AC-3¢, reverse 5¢-ATT
GGG ACA GCT TGG ATC A-3¢ and internal
probe 5¢-FAM-CAC CTG GGC AGC TGC
CAA-BHQ1-3¢; GAPDH forward 5¢-ATT CCA
CCC ATG GCA AAT TC-3¢, reverse 5¢-GAT
GGG ATT TCC ATT GAT GAC A-3¢ and
internal probe 5¢-FAM-CCG TTC TCA GCC
TTG ACG GTG C-BHQ1-3¢; CYP forward 5¢-
TGG ACT TCT AGT GAT GAG AAA GAT
TGA-3¢, reverse 5¢-CAC TGC GAG ATC ACC
ACA GGT A-3¢ and internal probe 5¢-FAM-TTC
CCA CAGGCC CCA ACA ATA AGC C-BHQ1-
3¢. Cycling was performed as for the gDNA
detection assay.
Results
We wanted to determine the incidence of EG-
FRvIII expression in breast cancer in order to
evaluate its potential as a target for tumor specific
cancer therapies. We began by screening 55 tumor
cell lines for EGFRvIII expression using a reverse
transcriptase polymerase chain reaction (RT-PCR)
assay that can simultaneously detect both the
EGFRwt and EGFRvIII mRNA. As a positive
control for EGFRvIII expression we isolated
RNA from MCF-7 breast cancer cells transfected
with an EGFRvIII expression construct (MCF-7/
EGFRvIII) as described previously [12]. The RT-
PCR products were separated on 2% agarose gels.
The EGFRwt and EGFRvIII produced a 1153-
Figure 1. Analysis of EGFRwt and EGFRvIII mRNA expression in a panel of breast cancer cell lines by reverse-transcription
polymerase chain reaction (RT-PCR). Total RNA was extracted from 9 cell lines, reverse transcribed and PCR amplified using primers
flanking the deleted region in EGFRvIII (a). MCF-7 cells transfected with EGFRvIII cDNA were used as a positive control. Products
were resolved on a 2% gel and stained with SYBR Green 1. The EGFRwt produces a 1153-bp product while the EGFRvIII produces
a smaller 352-bp product. GAPDH is shown as a control for RNA (b). * A faint but clearly visible 1153-bp band in the column labeled
MCF-7 was lost when the image was formatted for publication.
JM Rae et al.90
Table 1. Fifty five cell lines were screened for EGFRwt and EGFRvIII expression by RT-PCR
Cell line Tumor type EGFRwt EGFRvIII
MCF-7vIII Breast ± ++
MCF-7 Breast + )
MDA MB 468 Breast ++++ )
MDA MB 231 Breast +++ )
SKBr-3 Breast ++ )
SKOV-3 Ovarian ++ )
MDA MB 435 Melanoma ) )
LCC-6 Melanoma ) )
SW-620 Colorectal + )
LS-174T Colorectal ± )
HepG2 Hepatocellular ± )
Hep3B Hepatocellular + )
A-431 Epidermoid ++++ )
UCSF interspore breast cancer cells
HCC-202 Breast +++ )
HCC-38 Breast ++ )
HBL-100 Breast ++ )
DU-4475 Breast ) )
BT-549 Breast ++ )
BT-483 Breast ± )
BT-474 Breast + )
BT-20 Breast ++++ )
600-MPE Breast + )
HCC-3153 Breast ++ )
HCC-2185 Breast +++ )
HCC-2157 Breast ± )
HCC-1954 Breast +++ )
HCC-1937 Breast +++ )
HCC-1569 Breast + )
HCC-1428 Breast + )
HCC-1143 Breast ++ )
HCC-1007 Breast ) )
MDA MB 435 Melanoma ) )
MDA MB 415 Breast ) )
MDA MB 361 Breast ++ )
MDA MB 231 Breast +++ )
MDA MB 134VI Breast ) )
MDA MB 157 Breast ++ )
MCF-7 Breast + )
LY-2 Breast ++ )
HS-578T Breast +++ )
SUM-185 Breast ) )
SUM-159 Breast ++ )
SUM-149 Breast ++ )
SUM-52 Breast ) )
SUM-44 Breast ) )
(Continued on next page)
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and 352-bp band, respectively as shown schemat-
ically in Figure 1(a). Only the MCF-7 cells trans-
fected with the EGFRvIII construct expressed
EGFRvIII while EGFRwt was expressed at vari-
able levels in the majority of cells as shown in
Figure 1(b). These results were confirmed by
repeating all assays at least three times. Also
shown are the RT-PCR products for GAPDH as a
control for RNA integrity and loading. Using this
method, we assayed 5 breast, 1 ovarian, 2 mela-
noma, 2 colorectal, 2 hepatocellular and 1 epi-
dermoid cancer cell lines. EGFRvIII was not
detected in any of these cells while EGFRwt was
found to be expressed at varying levels in all cells
except for the MDA MB 435 cells and LCC-6, a
variant of that line.
We were unable to detect endogenous EG-
FRvIII expression in our initial screen which
contained only a small number of breast cancer
cell lines. Therefore, to better characterize its
Table 1. (Continued)
Cell line Tumor type EGFRwt EGFRvIII
SKBr-3 Breast ++ )
MDA MB 468 Breast ++++ )
MDA MB 453 Breast ) )
MDA MB 436 Breast +++ )
ZR 75-30 Breast ) )
ZR 75-B Breast ) )
ZR 75-1 Breast ++ )
T-47D Breast + )
SUM-1315 Breast +++ )
SUM-190 Breast + )
Five breast, 1 ovarian, 2 melanoma, 2 colorectal, 2 hepatocellular and 1 epidermoid cancer cell lines were cultured from frozen stocks,
RNA was extracted and assayed along with RNA extracts from an additional 42 breast cancer cell lines obtained from the UCSF
Interspore shared resource. No expression is indicated with a ()) and positive expression is shown qualitatively with (±) representing
barely detectable up to (++++) representing high mRNA expression.
Figure 2. Real-time RT-PCR analysis of EGFRwt and EGFRvIII expression in RNA extracted from formalin fixed paraffin-
embedded tumor cell lines. Cell pellets were made from cultured tumor cell lines then formalin fixed and paraffin embedded. Samples
were sectioned, RNA isolated, and mRNA levels determined by real-time RT-PCR analysis as described in the materials and methods
section. Shown are the normalized fold expression levels of EGFRwt (open bars) and EGFRvIII (filled bars) each normalized to the
same two housekeeping genes. GAPDH and CYP, and represents the mean of triplicates determinations.
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expression we obtained RNA samples from 42
breast cancer cell lines from the University of
California San Francisco InterSpore cell reposi-
tory where a collection of breast cancer cells lines
from various institutions are maintained. Again
not a single cell line was found to express EG-
FRvIII while variable expression of EGFRwt was
detected in the majority of samples. The results
from all the cell lines are shown in Table 1 where
the grading system used for expression ranges
from undetectable ()) to high expression
(++++).
Tumor cells grown in vitro must undergo
adaptive changes in order to survive tissue culture
conditions and therefore, the absence of detectable
EGFRvIII in tissue culture cells might be an
in vitro artifact and not truly represent the in vivo
expression. To test this hypothesis, we used real-
time RT-PCR to measure EGFRwt and EG-
FRvIII in 170 formalin fixed paraffin embedded
primary breast cancers. We chose real-time RT-
PCR because it is more reliable as a quantitative
assay than other RT-PCR methods. Primers and a
fluorogenic probe where designed across the exon
2/exon 7 breakpoint as shown in Figure 2(a) (se-
quence of primers and probe are shown as capital
letters). This Taqman assay was first tested on a
synthetic template and four glioblastoma formalin
fixed paraffin embedded samples (data not shown).
This assay gave a reliable signal when an
EGFRvIII synthetic template was used in the
reaction. Out of the four glioblastoma samples
investigated, two were positive for the presence of
EGFRvIII and two were negative for the variant.
It was determined that the assay could reproduc-
ibly detect the synthetic template down to
approximately 10 copies per reaction mix. It was
also able to detect the presence of EGFRvIII in the
two positive glioblastoma samples from as little as
0.05 ng input RNA per assay well.
To further test sensitivity and specificity of our
real-time PCR assay we had cell pellets from
several tumor cell lines, including cells transfected
with an EGFRvIII expression construct, formalin
fixed and paraffin embedded. The samples were
then sectioned and RNA was isolated as described
in the materials and methods section. The extracts
were assayed in a blinded fashion, for both
EGFRwt and EGFRvIII mRNA expression and
normalized to two reference normalization genes
(GAPDH and CYP). The CT values are plotted
in Figure 2(b). Included in the assay were the
two glioblastoma samples previously testing po-
sitive for EGFvIII mRNA expression. In addition,
we analyzed RNA extracted from two separate
MCF-7 and MCF-7/EGFRvIII cell pellets which
were processed on separate days and formalin
fixed over different periods of time (1–7 days).
Shown in the open bars are the normalized CT
values for EGFRwt while the filled bars represent
the variant EGFRvIII. The expression of EG-
FRwt varied considerably but was detected in all
samples except for the MDA MB 435 cells (not
plotted). The expression of EGFRvIII was readily
detectable in the MCF-7/EGFRvIII transfectants
and glioblastoma samples but not in any of the
breast cancer cell lines including the MDA MB
435 cells.
Having validated the real-time RT-PCR for
sensitivity and specificity, we then screened a total
of 170 primary breast cancers for EGFRwt and
EGFRvIII. The samples included 153 invasive
ductal carcinomas and 17 invasive lobular carci-
nomas collected between 1990 and 1997. To con-
trol for RNA quality, the expression of EGFRwt
and EGFRvIII was normalized to two reference
normalization genes as described above. As shown
in Figure 3, in these samples the normalized
expression levels of EGFRwt varied over a three
log range. Despite being able to readily detect
























Figure 3. EGFRwt expression in 170 primary breast cancers.
Real-time RT-PCR was used to examine EGFRwt and EG-
FRvIII expression in formalin fixed paraffin embedded primary
breast cancers. The samples were sectioned, RNA isolated,
DNase treated, assayed for gDNA contamination then screened
for mRNA expression by real-time RT-PCR analysis as de-
scribed in the materials and methods section. Since all samples
were negative for EGFRvIII (CT values of 40), only the results
for EGFRwt are shown. Shown are the mean CT values nor-
malized to two reference normalization genes (duplicates
determinations).
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we were unable to detect the expression of EG-
FRvIII in any of these samples.
Discussion
In this study we were unable to detect measurable
levels of EGFRvIII expression in any tumor cell
line or primary breast cancer RNA, despite being
able to detect a wide range of EGFRwt expression.
Our results are consistent with the recent paper
from Jungbluth et al. who, using immunohisto-
chemistry with well characterized antibodies for
EGFRwt and EGFRvIII, show that EGFRvIII
was undetectable in 10 out of 10 breast primary
cancers [10]. These results are in contrast to those
published by other investigators who have found
EGFRvIII protein in primary breast cancers as
well as in other cancers [7–9]. These conflicting
reports may reflect differences in the antibodies or
protocols used for immunohistochemical staining
in these studies. To avoid this issue, we chose to
measure mRNA levels using rigorously tested and
controlled RT-PCR and real-time PCR assays. Our
results are consistent with those of Tidow et al. who
were unable to detect EGFRvIII mRNA in any of
their 23 primary breast cancers, results which were
confirmed by Western blot analysis [11]. These
findings along with ours are in contrast to those of
Ge et al. who used RT-PCR as well as immuno-
histochemistry to detect EGFRvIII in primary
breast cancer [9]. Their results showed that 67.8%
(19/28) of primary breast cancers had detectable
levels of EGFRvIII mRNA and 57.8% (11/19) were
positive for protein expression by immunohisto-
chemical staining. There are several reasons for
these conflicting results. One possibility is sampling
bias, which seems unlikely because of the large
number (n ¼ 170) of primary breast tumors as-
sayed by our group and the 23 samples assayed by
Tidow et al. Furthermore, Ge et al. detected EG-
FRvIII in a high proportion of tumors. It is not
likely that EGFRvIII mRNA was expressed below
the detection level of the assay since; using this
method we were readily able to detect expression in
positive control MCF-7/EGFRvIII transfected
cells as well as in two glioblastoma samples. Fur-
thermore, we were able to detect the expression of
EGFRvIII mRNA over a three log range. In the
study by Ge et al., a limited amount of tissue pre-
pared by microdissection was extracted and
assayed using a nested PCR approach with a 3¢
mismatch primer. A disadvantage of this approach
is that extremely high levels of amplification are
required, which could generate non-specific prod-
ucts and may produce false positive results [14].
Unfortunately, samples described in the nested
PCR study were not available to make a direct
comparison of the two methodologies. However, a
direct comparison was made of the non-nested
PCR approach using the LCC-6 cell line. Despite
our repeated attempts, we were unable to detect
EGFRvIII mRNA in this cell line, in contrast to
the results published by Lou et al. [13].
Our results show that paraffin embedded tissue
samples can be successfully interrogated formRNA
expression by real-time PCR. Recently, this tech-
nique was used to measure the levels of 7 reference
genes and 185 cancer-related genes in 146 paraffin
embedded breast cancer specimens, the details of
which have been presented elsewhere [15]. The
complete absence of EGFRvIII expression in the
cell lines and primary breast cancers was surprising.
It is possible that EGFRvIII is expressed at such a
low level that it can only be detected by using two
rounds of PCR amplification, however, it is not
clear what significance this expression may be.
Further, others have shown real-time RT-PCR to
be superior to nested RT-PCR because it maintains
the same level of sensitivity while decreasing the
incidence of false-positive results [16].
Our study shows that EGFRvIII mRNA
expression is not detectable in any of the investi-
gated breast cancer cell lines or a large number of
primary breast cancers. In contrast, the majority of
these samples do express EGFRwt at various levels.
Given that there is higher expression of EGFRwt,
that it has a multitude of ligands and that it can be
transactivated in several of ways, it is doubtful that
EGFRvIII is a major drive of these breast cancers
from the standpoint of the EGFR pathway. From
these results, we conclude that EGFRvIII does not
play a role in breast cancer and, therefore, does not
represent a viable target for therapy. We are now
actively examining other tumor types for expression
of the EGFRvIII gene product.
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